2023-01-01 - 2023-03-31 (third quarter)
- Results after tax for the quarter amounted to -3.2 MSEK (-5.6 MSEK)
- Revenues for the quarter amounted to 2 KSEK (0 KSEK)
- Earnings per share for the quarter amounted to
-0.115 SEK (-0.397 SEK )
2022-07-01 - 2023-03-31 (nine-month period)- Results after tax for the period amounted to -15.3 MSEK (-15.0 MSEK)
- Revenues for the period amounted to 5 KSEK (0 KSEK)
- Earnings per share for the period amounted to
-0.549 SEK (-1.053 KSEK)SEK
Highlights during the period
In
In
Highlights after the period
In
CEO
The recent period has been intense for
Candidates based on next generation vaccine technology
In the beginning of the year, we decided to develop a chlamydia vaccine candidate based on next-generation vaccine technology, mRNA, as vaccines based on mRNA technology show great clinical potential to drive both antibodies and T cells. In connection with this, we decided to pause the development of the protein-based chlamydia candidate until further notice, as it requires large resources, and instead focus on the mRNA technology, which also gives us good opportunities to achieve synergies with our two vaccine candidates. We are convinced that the mRNA candidate has very good potential and it is positive that it is covered by the same patent and the exclusive global license agreement with Spixia Biotechnology.
We have a continued intensive year ahead of us where we plan further studies to determine which technology the vaccine candidate against HSV-2 should be based on. At the end of last year, we conducted a first preclinical study with the candidate, where the results for our mRNA-based candidate were outstanding and could show that the antibody response was at least equivalent to the protein-based vaccine. The results also showed that the mRNA candidate elicits a superior T-cell response that is in line with T-cell responses detectable after recovery from an HSV-2 infection. We also look forward to initiating process development and other preparations for toxicology and clinical trials with our mRNA-based vaccine candidates.
Demanded expertise within the Company
In mid-February, Dr.
Finally, as we approach the end of the financial year, I would like to thank the team for their efforts so far. I look back on an eventful year for
Please join us at upcoming activities in our Calendar, and see our latest presentations from Sedermeradagen Malmö on 5 October and Aktieportföljen Live on 11 October (both in Swedish).
Hans Arwidsson, Ph.D., MBA
CEO of
hans.arwidsson@eurocine-vaccines.com
+46 70 634 0171
Through its portfolio strategy, innovative vaccine candidates are given the opportunity to reach the market quicker, while investors are offered risk diversification with a big future leverage. These candidates are later licensed to partners for commercialization.
Listed at
https://news.cision.com/eurocine-vaccines/r/eurocine-vaccines-discloses-interim-report-for-july-2022---march-2023,c3773532
https://mb.cision.com/Main/11552/3773532/2077419.pdf
https://mb.cision.com/Public/11552/3773532/ad55e6ff92f68526.pdf
(c) 2023 Cision. All rights reserved., source